NCT00150618View on ClinicalTrials.gov

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

PHASE3CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

March 30, 2004

Primary Completion Date

October 7, 2004

Study Completion Date

October 7, 2004

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

SPD503 (1 mg)

DRUG

SPD503 (2 mg)

DRUG

SPD503 (3 mg)

DRUG

SPD503 (4 mg)

DRUG

Placebo

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY